Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$16 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-8 Mln
ROE
-4.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
17.3
Industry P/E
--
EV/EBITDA
-1.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.9
Face value
--
Shares outstanding
24,463,700
CFO
$-147.64 Mln
EBITDA
$-172.27 Mln
Net Profit
$-181.55 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Acer Therapeutics Inc. (DE) (ACER)
| -73.7 | -22.4 | -9.2 | -44.1 | -38.4 | -50.7 | -42.8 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Acer Therapeutics Inc. (DE) (ACER)
| 10.1 | -13.0 | -34.7 | -80.1 | 45.0 | 45.4 | -66.8 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Acer Therapeutics Inc. (DE) (ACER)
|
0.7 | 16.2 | 0.4 | -60.9 | -3,716.2 | -- | -- | 17.3 |
| 3.4 | 93.0 | 1.0 | -27.1 | -2,935.3 | -125.1 | -- | 6.0 | |
| 3.5 | 8.2 | 0.0 | -39.4 | -- | -54.6 | -- | 0.4 | |
| 228.7 | 43,154.8 | 2,300.4 | -750.2 | -35.0 | -28.5 | -- | 16.9 |
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising... EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts. As of November 17, 2023, Acer Therapeutics Inc. operates as a subsidiary of Zevra Therapeutics, Inc. Read more
Founder, Pres, CEO & Director
Mr. Christopher Schelling
Founder, Pres, CEO & Director
Mr. Christopher Schelling
Headquarters
Newton, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Acer Therapeutics Inc (DE) (ACER) is $0.66 (NASDAQ) as of 20-Nov-2023 16:00 EDT. Acer Therapeutics Inc (DE) (ACER) has given a return of -38.37% in the last 3 years.
Since, TTM earnings of Acer Therapeutics Inc (DE) (ACER) is negative, P/E ratio is not available.
The P/B ratio of Acer Therapeutics Inc (DE) (ACER) is 17.26 times as on 19-Dec-2023, a 338 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-1.44
|
-2.40
|
|
2021
|
-2.17
|
-18.52
|
|
2020
|
-1.26
|
3.50
|
|
2019
|
-1.39
|
2.18
|
|
2018
|
-8.51
|
4.02
|
The 52-week high and low of Acer Therapeutics Inc (DE) (ACER) are Rs -- and Rs -- as of 02-Apr-2026.
Acer Therapeutics Inc (DE) (ACER) has a market capitalisation of $ 16 Mln as on 19-Dec-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Acer Therapeutics Inc (DE) (ACER), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.14
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.